The PD-1 immune checkpoint inhibitor nivolumab achieved an ORR of 15% with a median duration of response that was not yet reached at a median 11-month follow-up for patients with advanced, refractory NSCLC.
- A Network of Your PeersView more >>
Most Popular Right Now
Gary M. Kirsh, MD, Earl L. Walz, and Pamela Skurkay discuss the integration of the autologous cellular immunotherapy sipuleucel-T (Provenge) into clinical practice for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. View Now